FDA places partial hold on Immunomedics' Phase II pancreatic cancer drug trial
This article was originally published in Scrip
Executive Summary
The US FDA placed a partial clinical hold on the ongoing Phase Ib/II trial of Immunomedics' investigational radiolabelled antibody for advanced pancreatic cancer, clivatuzumab tetratexan, after one patient was given a higher-than-prescribed dose at one of its trial sites. The firm says that patient remains on study "with no critical toxicity".